Medical College of Wisconsin
CTSIResearch InformaticsREDCap

Molly H. Allbee-Johnson BA, MPH

Program Manager II

Institution: Medical College of Wisconsin
Department: Center for International Blood and Marrow Transplant Research

Publications (14)

  • Corrigendum to: Current Activity Trends and Outcomes in Hematopoietic Cell Transplantation and Cellular Therapy - A Report from the CIBMTR, Transplantation and Cellular Therapy, 31:8, August 2025, 505-532; Article Number: JTCT-S-25-00377. (Spellman SR, Xu K, Oloyede T, Ahn KW, Akhtar OS, Bolon YT, Broglie L, Bloomquist J, Bupp C, Chen M, Devine SM, Jurdi NE, Hamadani M, Hengen M, Huppler AH, Jaglowski S, Kuxhausen M, Lee SJ, Moskop A, Page KM, Pasquini MC, Pérez WS, Phelan R, Rizzo D, Saber W, Stefanski HE, Steinert P, Tuschl E, Visotcky A, Vogel R, Auletta JJ, Shaw BE, Allbee-Johnson M) Transplant Cell Ther 2025 Oct 07 PMID: 41027557 PMCID: PMC12606686 SCOPUS ID: 2-s2.0-105018107118 10/01/2025    
  • Current Activity Trends and Outcomes in Hematopoietic Cell Transplantation and Cellular Therapy - A Report from the CIBMTR. (Spellman SR, Xu K, Oloyede T, Ahn KW, Akhtar O, Bolon YT, Broglie L, Bloomquist J, Bupp C, Chen M, Devine SM, El-Jurdi N, Hamadani M, Hengen M, Huppler AH, Jaglowski S, Kuxhausen M, Lee SJ, Moskop A, Page KM, Pasquini MC, Perez W, Phelan R, Rizzo D, Saber W, Stefanski HE, Steinert P, Tuschl E, Visotcky A, Vogel R, Auletta JJ, Shaw BE, Allbee-Johnson M) Transplant Cell Ther 2025 Aug;31(8):505-532 PMID: 40398621 PMCID: PMC12302970 SCOPUS ID: 2-s2.0-105009874373 05/22/2025       38 Citations
  • Donor Type Does Not Impact Late Graft Failure Following Reduced-Intensity Allogeneic Hematopoietic Cell Transplantation with Post-Transplant Cyclophosphamide-Based Graft-Versus-Host Disease Prophylaxis. (Hickey CL, Zhang MJ, Allbee-Johnson M, Romee R, Majhail NS, Malki MMA, Antin JH, Benjamin CL, Bredeson C, Chhabra S, Grunwald MR, Inamoto Y, Kanakry CG, Milano F, Soiffer RJ, Solomon SR, Spellman SR, Brunstein CG, Cutler C) Transplant Cell Ther 2025 Mar;31(3):174.e1-174.e12 PMID: 39755256 PMCID: PMC11875877 SCOPUS ID: 2-s2.0-85215830493 01/05/2025       4 Citations
  • Outcomes of patients with primary central nervous system lymphoma following CD19-targeted chimeric antigen receptor T-cell therapy. (Mercadal S, Ahn KW, Allbee-Johnson M, Ganguly S, Geethakumari PR, Hong S, Malone A, Murthy H, Pawarode A, Sica AR, Solh M, Ustun C, Shadman M, Sauter CS, Hamadani M, Herrera AF, Lee CJ) Haematologica 2025 Jan 01;110(1):218-221 PMID: 39234871 PMCID: PMC11694114 SCOPUS ID: 2-s2.0-85214317988 09/05/2024       8 Citations
  • The health risk of social disadvantage is transplantable into a new host. (Turcotte LM, Wang T, Beyer KM, Cole SW, Spellman SR, Allbee-Johnson M, Williams E, Zhou Y, Verneris MR, Rizzo JD, Knight JM) Proc Natl Acad Sci U S A 2024 Jul 23;121(30):e2404108121 PMID: 39008669 PMCID: PMC11287259 SCOPUS ID: 2-s2.0-85199015473 07/15/2024       3 Citations
  • CD19-directed CART therapy for T-cell/histiocyte-rich large B-cell lymphoma. (Pophali PA, Fein JA, Ahn KW, Allbee-Johnson M, Ahmed N, Awan FT, Farhan S, Grover NS, Hilal T, Iqbal M, Maakaron J, Modi D, Nasrollahi E, Schachter LG, Sauter C, Hamadani M, Herrera A, Shouval R, Shadman M) Blood Adv 2024 Oct 22;8(20):5290-5296 PMID: 38985302 PMCID: PMC11497379 SCOPUS ID: 2-s2.0-85204053172 07/10/2024       17 Citations
  • Current Trends and Outcomes in Cellular Therapy Activity in the United States, Including Prospective Patient-Reported Outcomes Data Collection in the Center for International Blood and Marrow Transplant Research Registry. (Cusatis R, Litovich C, Feng Z, Allbee-Johnson M, Kapfhammer M, Mattila D, Akinola I, Phelan R, Broglie L, Auletta JJ, Steinert P, Bolon YT, Akhtar O, Bloomquist J, Chen M, Devine SM, Bupp C, Hamadani M, Hengen M, Jaglowski S, Kaur M, Kuxhausen M, Lee SJ, Moskop A, Page KM, Pasquini MC, Rizzo D, Saber W, Spellman SR, Stefanski HE, Tuschl E, Yusuf R, Zhan K, Flynn KE, Shaw BE) Transplant Cell Ther 2024 Sep;30(9):917.e1-917.e12 PMID: 38944153 PMCID: PMC11587342 SCOPUS ID: 2-s2.0-85199289175 06/30/2024       67 Citations
  • Leveraging Hematopoietic Cell Transplant Data and Biorepository Resources at the Center for International Blood and Marrow Transplant Research to Improve Patient Outcomes. (Bolon YT, Atshan R, Allbee-Johnson M, Estrada-Merly N, Auletta JJ, Broglie L, Cusatis R, Page KM, Phelan R, Sajulga R Jr, Shaw BE, Spahn A, Steinert P, Stewart V, Vierra-Green C, Lee SJ, Spellman SR) Transplant Cell Ther 2024 Sep;30(9):921.e1-921.e22 PMID: 38871054 PMCID: PMC11809440 SCOPUS ID: 2-s2.0-85198556368 06/14/2024       2 Citations
  • Outcomes of patients with secondary central nervous system lymphoma treated with chimeric antigen receptor T-cell therapy: A CIBMTR analysis. (Epperla N, Hashmi H, Ahn KW, Allbee-Johnson M, Chen AI, Wirk B, Kanakry JA, Lekakis L, Kharfan-Dabaja MA, Scordo M, Riedell PA, Jain T, Shadman M, Sauter C, Hamadani M, Herrera AF, Ahmed S) Br J Haematol 2024 Sep;205(3):1202-1207 PMID: 38797526 PMCID: PMC11499028 SCOPUS ID: 2-s2.0-85194474176 05/27/2024       10 Citations
  • Noninfectious Pulmonary Toxicity after Allogeneic Hematopoietic Cell Transplantation. (Patel SS, Ahn KW, Khanal M, Bupp C, Allbee-Johnson M, Majhail NS, Hamilton BK, Rotz SJ, Hashem H, Beitinjaneh A, Lazarus HM, Krem MM, Prestidge T, Bhatt NS, Sharma A, Gadalla SM, Murthy HS, Broglie L, Nishihori T, Freytes CO, Hildebrandt GC, Gergis U, Seo S, Wirk B, Pasquini MC, Savani BN, Sorror ML, Stadtmauer EA, Chhabra S) Transplant Cell Ther 2022 Jun;28(6):310-320 PMID: 35314376 PMCID: PMC9197865 SCOPUS ID: 2-s2.0-85129519446 03/23/2022       24 Citations
  • Does recipient body mass index inform donor selection for allogeneic haematopoietic cell transplantation? (Abou-Ismail MY, Fraser R, Allbee-Johnson M, Metheny L 3rd, Ravi G, Ahn KW, Bhatt NS, Lazarus HM, de Lima M, El Jurdy N, Hematti P, Beitinjaneh AM, Nishihori T, Badawy SM, Sharma A, Pasquini MC, Savani BN, Sorror ML, Stadtmauer EA, Chhabra S) Br J Haematol 2022 May;197(3):326-338 PMID: 35286719 PMCID: PMC9675037 SCOPUS ID: 2-s2.0-85126235994 03/15/2022       1 Citation
  • Umbilical Cord Blood or HLA-Haploidentical Transplantation: Real-World Outcomes versus Randomized Trial Outcomes. (O'Donnell PV, Brunstein CG, Fuchs EJ, Zhang MJ, Allbee-Johnson M, Antin JH, Leifer ES, Elmariah H, Grunwald MR, Hashmi H, Horowitz MM, Magenau JM, Majhail N, Milano F, Morris LE, Rezvani AR, McGuirk JP, Jones RJ, Eapen M) Transplant Cell Ther 2022 Feb;28(2):109.e1-109.e8 PMID: 34775146 PMCID: PMC8882346 SCOPUS ID: 2-s2.0-85121144074 11/15/2021       22 Citations
  • Planned Granulocyte Colony-Stimulating Factor Adversely Impacts Survival after Allogeneic Hematopoietic Cell Transplantation Performed with Thymoglobulin for Myeloid Malignancy. (Orfali N, Zhang MJ, Allbee-Johnson M, Boelens JJ, Artz AS, Brunstein CG, McNiece IK, Milano F, Abid MB, Chee L, Diaz MA, Grunwald MR, Hematti P, Hsu J, Lazarus HM, Munshi PN, Prestidge T, Ringden O, Rizzieri D, Riches ML, Seo S, Solh M, Solomon S, Szwajcer D, Yared J, van Besien K, Eapen M) Transplant Cell Ther 2021 Dec;27(12):993.e1-993.e8 PMID: 34507002 PMCID: PMC8671234 SCOPUS ID: 2-s2.0-85120751167 09/11/2021       9 Citations
  • Comparison of haploidentical and umbilical cord blood transplantation after myeloablative conditioning. (Wagner JE, Ballen KK, Zhang MJ, Allbee-Johnson M, Karanes C, Milano F, Verneris MR, Eapen M, Brunstein CG) Blood Adv 2021 Oct 26;5(20):4064-4072 PMID: 34461630 PMCID: PMC8945645 SCOPUS ID: 2-s2.0-85118551689 08/31/2021       30 Citations
    • Last update: 02/12/2026